Drug Database · Clinicians

Metronidazole

Brands (128) Amizol, Flagyl, Medgyl…Show all
Amizol · Flagyl · Medgyl · Protozole · Aldazole · Aldezol · Ambidazol · Dazomet · Jinzole · Menizole · Metronova IV · Metrozole · Moniliasol · Neorobic · Newmet · Nicozole · Patryl · Ricozole · Rodazid · Siti-zole · Acumet · Affozole · Altozol IV · Amibazole · Amrid · Anerobizol · Antizoal · Apzole · Axagyl · Axamet-IV · Bacdazole · Bacimex · Berrydazole · Bestdazole · Bluemedzole · Cetaz · Coremedazole · Daryl · Dazoled · Delexigyl · Dymetrazole · Dynazole · Eastmezol · Endigly · Erzol · Eurogyl · Euromet · Flagex · Flagidin · Flagimax · Flagyl Forte · Flagyzole · Flamibazid 500 · Flatro · Flazole · Foramebex · Frotin · G-Trozole · Godazole · Gonidazole · Gorondaz · Medgyl IV · Medicazol · Medizole · Medzol · Metamet · Metdazid · METRAZOL · Metrinox IV · Metris · Metro-Brill · Metrocare · Metroclear · Metrocor · Metroden · Metrogem · Metrogil · Metrogyl · Metrolev · Metroneed · Metronex S · Metronizol · Metronova · Metrony · Metrosaph · Metrosaph-500 · Metrosave · Metrosol · Metroton · Metrovee · Metrovia · Metrovin · Metroxcel · Metroxid · Metrozed · Metrozen · Metrynal · Metzole · Mistol · Mordole · Navgyl Forte · Navgyl-500 · Neorobia · Nidaz · Nidazoprime · Nirmet · Onizole · Onizole Vial · Patrizole · Polgyl · Progyl Ds · Q-Zol · Quinozole · Retazol · Rockzole · Strozole-500 · Sydenzole · TG-ZOLE · Triconex Forte · Trimetro IV · Trinosaph · Trozodaz · Vitazol · Xylomid · Zol · Zolegyl · Zolemet · Zolpas

Nitroimidazole Antimicrobial US FDA class
Antiprotozoal (nitroimidazole derivative); Antiprotozoal (imidazole derivative); and others PH FDA category

No kidney change; dose after HDRx · Prescription drug173 PH productsPNF-listedPhilHealth GAMOT Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 902ab25b-d493-495a-884e-96b080e9f72d, version date November 21, 2025 (Metronidazole · Civica, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis , B. distasonis , B. ovatus , B. thetaiotaomicron…
  • Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults.
  • Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species…
  • Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species in adults.
  • Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group in adults.
  • Central Nervous System (CNS) Infections , including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group in adults.
  • Lower Respiratory Tract Infections , including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group in adults.
  • Endocarditis caused by Bacteroides species including the B. fragilis group in adults.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Treatment of Anaerobic Bacterial Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibacterial drugs appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection.

Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin.

  • Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species in adults and pediatric patients less than 4 months of age.
  • Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults.
  • Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults.
  • Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species in adults.
  • Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group in adults.
  • Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group in adults.
  • Lower Respiratory Tract Infections, including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group in adults.
  • Endocarditis caused by Bacteroides species including the B. fragilis group in adults. Prophylaxis Indication The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively and postoperatively may reduce the incidence of postoperative infection in adult patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Hypersensitivity to metronidazole or other nitroimidazoles
  • Disulfiram within the past 2 weeks
  • Alcohol or propylene glycol during and for 3 days after therapy
  • Cockayne syndrome
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

CONTRAINDICATIONS

  • Hypersensitivity Metronidazole Injection is contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives.
  • Psychotic Reaction with Disulfiram Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see PRECAUTIONS-Drug Interactions).
  • Interaction with Alcohol Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see PRECAUTIONS-Drug Interactions).
  • Cockayne Syndrome Metronidazole Injection is contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with Cockayne syndrome (see ADVERSE REACTIONS).

Dosing: Adult

  • Anaerobic infections (IV, adults): Loading 15 mg/kg over 1 hour (about 1 g), then 7.5 mg/kg (about 500 mg) every 6 hours, starting 6 hours later
  • Oral step-down (adults): 7.5 mg/kg (about 500 mg) every 6 hours
  • Maximum: 4 g per 24 hours
  • Severe hepatic impairment (Child-Pugh C): Reduce dose by 50%
  • Hemodialysis: Give after the session or add a supplement
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Dosage, rate of administration, and duration of treatment are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition and concomitant treatment, and on the patient’s clinical and laboratory response to the treatment. Recommended Dosage for the Treatment of Anaerobic Bacterial Infections The recommended dosage schedule for adults for the treatment of anaerobic infections is presented in the Table 1: Table 1.

Recommended Dosage Schedule for the Treatment of Anaerobic Bacterial Infections in Adults Loading Dose 15 mg/kg infused intravenously over one hour (approximately 1 gram for a 70-kg adult). Maintenance Dosage 7.5 mg/kg infused intravenously over one hour every six hours (approximately 500 mg for a 70-kg adult). The first maintenance dose should be instituted six hours following the initiation of the loading dose.

Parenteral therapy may be changed to oral metronidazole therapy when conditions warrant, based upon the severity of the disease and the response of the patient to treatment with Metronidazole Injection. The usual adult oral dosage is 7.5 mg/kg every six hours (approximately 500 mg for a 70-kg adult). A maximum of 4 grams should not be exceeded during a 24-hour period.

The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract and endocardium may require longer treatment. Recommended Dosage for the Treatment of Intra-Abdominal Infections in Pediatric Patients Less than 4 Months of Age: The recommended dosage schedule for pediatric patients less than 4 months of age for the treatment of intra-abdominal infections is described in Table 2 below.

These dosage schedules achieve drug exposures in pediatric patients similar to adults treated with Metronidazole Injection for this indication. Table 2. Recommended Dosage Schedule for the Treatment of Intra-Abdominal Infections in Pediatric Patients Less than 4 months of Age Post-menstrual age (Completed weeks) Loading Dose (mg/kg) Maintenance Dose The first maintenance dose is given 24 hours after the start of the loading dose.

(mg/kg) Dosing interval (hours) 23 to <34 15 7.5 12 34 to 40 15 7.5 8 >40 to 48 15 7.5 6 Recommended Dosage in Patients with Severe Hepatic Impairment For patients with severe hepatic impairment (Child-Pugh C), the metronidazole dose should be reduced by 50% (see CLINICAL PHARMACOLOGY and PRECAUTIONS). Recommended Dosage in Patients Undergoing Hemodialysis Hemodialysis removes significant amounts of metronidazole and its metabolites from systemic circulation.

The clearance of metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of metronidazole cannot be separated from a hemodialysis session, supplementation of metronidazole dosage following a hemodialysis session should be considered, depending on the patient’s clinical situation (see CLINICAL PHARMACOLOGY).

Dosage Considerations in Geriatric Patients In elderly patients the pharmacokinetics of metronidazole may be altered and, therefore, monitoring of serum levels may be necessary to adjust the metronidazole dosage accordingly. Recommended Prophylaxis Dosage For surgical prophylactic use, to prevent postoperative infection in contaminated or potentially contaminated colorectal surgery, the recommended dosage schedule for adults is: a. 15 mg/kg infused over 30 to 60 minutes and completed approximately one hour before surgery; followed by b. 7.5 mg/kg infused over 30 to 60 minutes at 6 and 12 hours after the initial dose.

It is important that (1) administration of the initial preoperative dose be completed approximately one hour before surgery so that adequate drug levels are present in the serum and tissues at the time of initial incision, and (2) Metronidazole Injection be administered, if necessary, at 6-hour intervals to maintain effective drug levels. Prophylactic use of Metronidazole Injection should be limited to the day of surgery only, following the above guidelines.

Important Administration and Preparation Instructions Caution: Metronidazole Injection is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole Injection, unless compatibility is known. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion.

DO NOT USE EQUIPMENT CONTAINING ALUMINUM (e.g., NEEDLES, CANNULAE) THAT WOULD COME IN CONTACT WITH THE DRUG SOLUTION AS PRECIPITATES MAY FORM. Metronidazole Injection is incompatible with (includes but is not limited to): Aztreonam, Cefamandole nafate, Cefoxitin, Penicillin G. In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products (see DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER).

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless the solution is clear and the seal is intact.

Dosing: Altered kidney function

Metronidazole is metabolized in the liver; kidney impairment does not change its own kinetics, but its hydroxy and acetate metabolites build up in kidney failure. The US label gives no kidney dose change. Hemodialysis removes 40% to 65% of a dose, so give it after the session or add a supplement; CAPD removes little and needs no change. Severe liver impairment (Child-Pugh C) needs a 50% dose cut.

Kidney function measure: Label PK uses CrCl (mL/min); no kidney bands.

Show full dosing details
CrCl ≥60 mL/min
No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label).
CrCl 30–59 mL/min
No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label).
CrCl 15–29 mL/min
No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label).
CrCl <15 mL/min (not on dialysis)
No dose change: kidney impairment does not alter single-dose metronidazole kinetics (label). In end-stage kidney disease, peak levels of hydroxy-metronidazole were 2 times and of metronidazole acetate 5 times normal (label PK). Because metabolites accumulate in end-stage kidney disease, monitoring for metronidazole-associated adverse events is recommended (label).
Hemodialysis (intermittent)
Hemodialysis (4 to 8 hours) removes 40% to 65% of a dose. If dosing cannot be separated from the session, consider a supplemental dose after hemodialysis (label).
Peritoneal dialysis
No dose change on CAPD; a 7.5-hour peritoneal dialysis removed about 10% of a dose (label).
CRRT
Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
  • Dialyzable? Hemodialysis: yes (40% to 65% of a dose per 4- to 8-hour session, by membrane and duration). Peritoneal dialysis: little (about 10%) (label). Under 20% protein bound.
  • Monitoring Neurologic symptoms (encephalopathy, cerebellar signs, seizures, peripheral or optic neuropathy, aseptic meningitis); liver function in hepatic impairment; INR with warfarin; lithium and creatinine with lithium (label).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual pediatric dose (label).
eGFR 30–59
No pediatric kidney dosing in label. Specialist input.
eGFR 15–29
No pediatric kidney dosing in label. Specialist input.
eGFR <15 (not on dialysis)
No pediatric kidney dosing in label. Specialist input.
Hemodialysis (intermittent)
No pediatric kidney dosing in label. Specialist input.
Peritoneal dialysis
No pediatric kidney dosing in label. Specialist input.
CRRT
No pediatric kidney dosing in label. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

Renal Impairment Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. Subjects with end-stage renal disease (ESRD; CL CR = 8.1±9.1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of metronidazole acetate, compared to healthy subjects with normal renal function (CL CR = 126 ± 16 mL/min).

Thus, on account of the potential accumulation of metronidazole metabolites in ESRD patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS). Effect of Dialysis Following a single intravenous infusion or oral dose of metronidazole 500 mg, the clearance of metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

A hemodialysis session lasting for 4 to 8 hours removed 40% to 65% of the administered metronidazole dose, depending on the type of the dialyzer membrane used and the duration of the dialysis session. If the administration of metronidazole cannot be separated from the dialysis session, supplementation of metronidazole dose following hemodialysis should be considered (see DOSAGE AND ADMINISTRATION).

A peritoneal dialysis session lasting for 7.5 hours removed approximately 10% of the administered metronidazole dose. No adjustment in metronidazole dose is needed in ESRD patients undergoing CAPD.

Dosing: Pediatric

Approved ages
Intra-abdominal infections in infants under 4 months; other indications in adults (IV label).
Usual dose
Under 4 months, intra-abdominal infection: loading dose 15 mg/kg, then 7.5 mg/kg starting 24 hours later, every 12 hours (postmenstrual age 23 to under 34 weeks), every 8 hours (34 to 40 weeks) or every 6 hours (over 40 to 48 weeks) (label Table 2).
Maximum dose
As above (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

Pediatric Use Pediatric Patients Less than 4 Months of Age The safety and effectiveness of Metronidazole Injection have been established for the treatment of intraabdominal infections in pediatric patients from birth to less than 4 months. Use of Metronidazole Injection in this age group is supported by evidence from data in adults with additional pharmacokinetic and safety data in pediatric patients from birth to less than 4 months of age.

A partially randomized, open-label, phase 2/3 study of intravenous Metronidazole Injection in combination with other intravenous antibacterial drugs was conducted in 62 preterm infants (≤ 33 weeks gestational age at birth, and postnatal age <121 days) and 55 late pre-term and term infants (≥ 34 weeks gestational age at birth, and postnatal age <121 days), with complicated intra-abdominal infections. The primary objective of this study was to evaluate the safety of metronidazole-containing regimens, which were administered for up to 10 days.

The adverse reactions reported in patients receiving metronidazole-containing regimens were comparable to patients receiving other antibacterial regimens in the study and generally similar to adverse reactions described in adults. The safety and effectiveness of Metronidazole Injection in pediatric patients less than 4 months of age have not been established for (1) the treatment of anaerobic infections other than intra-abdominal infections or for (2) prophylaxis for postoperative infections (see INDICATIONS AND USAGE, CLINICAL PHARMACOLOGY, Pediatric Patients and DOSAGE AND ADMINISTRATION).

Pediatric Patients 4 Months of Age and Older The safety and effectiveness of Metronidazole Injection in pediatric patients 4 months of age and older have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. In geriatric patients, monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY, PRECAUTIONS). Decreased liver function in geriatric patients can result in increased concentrations of metronidazole that may necessitate adjustment of metronidazole dosage (see DOSAGE AND ADMINISTRATION).

Dosage forms

Philippines

  • Tablet: 250 mg, 500 mg
  • ) solution for i.v. infusion: 1 mg/mL (500 mg/100 mL, 5 mg/mL (500 mg/100 mL
  • Solution for iv infusion: 5 mg/mL, 500 mg per 100 mL, 500 mg/100 mL
  • Film-coated tablet: 500 mg
  • ) solution for intravenous infusion: 5 mg/mL (500 mg/100 mL
  • Oral suspension: 25 mg/mL, 125 mg/5 mL, 250 mg/5 mL
  • Suspension: 125 mg/5 mL
  • ) solution for injection: 5 mg/mL (500 mg/100 mL
  • ) solution for iv infusion: 5 mg/mL (500 mg/100 mL, 500 mg/100 mL (5 mg/mL
  • Solution for i.v. infusion: 5 mg/mL, 500 mg, 500 mg/100 mL

and 7 more forms; see the products table.

Registered products in the Philippines

173 products registered with the Food and Drug Administration (FDA) Philippines list Metronidazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products173
Philippine FDA-registered products for Metronidazole
Package insert
AcumetMetronidazole
5 mg/mL [500 mg/100 mL (0.5% w/v)] Solution for Intravenous Infusion.100 mL-net content Polyethylene Bottle with Euro Head Cap (Box of 1's)
Rx
Aculife Healthcare Private LimitedIndia
Blue Global (FZE)
DRP-14852
Jan 24, 2029
AffozoleMetronidazole
500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL
Rx
Ahlcon Parenterals (India) Ltd.India
Affomedz, Inc.Importer: I.E. Medica, Inc.
DRP-5630-01
Oct 17, 2029
AldazoleMetronidazole (as Benzoate)
125 mg/5 mL Suspension (Strawberry Flavor)Amber Bottle x 15 mL and 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-2440-01
May 19, 2031
AldazoleMetronidazole
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-3377-01
Mar 9, 2030
AldezolMetronidazole
5 mg/mL (500 mg/100 mL) Solution for IV InfusionFFS LDPE Bottle x 100 mL (Box of 1's)
Rx
Ahlcon Parenterals (India) Ltd.India
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-5629-03
Oct 17, 2029
AldezolMetronidazole
5mg/mL (500mg/100mL) Solution for IV InfusionWhite transparent LDPE bottle x 100 mL (Box of 1's)
Rx
Albert David LimitedIndia
Medethix, Inc.
DRP-7822
Apr 10, 2031
Altozol IVMetronidazole
500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL (Box of 1's)
Rx
Ahlcon Parenterals (India) Ltd.India
Altomed Pharmaceuticals, Inc.Importer: I.E. Medica, Inc.
DRP-5630-03
Oct 17, 2029
AmbidazolMetronidazole (as Benzoate)
125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5469
Mar 12, 2027
AmbidazolMetronidazole
250 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker’s Laboratories Inc.Philippines
—
DR-XY24776
Feb 8, 2029
AmibazoleMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
New Myrex Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-1001-01
Jan 30, 2028
AmizolMetronidazole (as Benzoate)
125 mg/5 mL Suspension (Strawberry Flavor)Amber Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc.
DRP-2440-02
May 8, 2031
AmizolMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. LtdIndia
Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc.
DRP-13577-01
Mar 13, 2028
AmizolMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Foramen Products Corporation
DR-XY22624
Mar 5, 2027
AmridMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Flamingo Pharmaceuticals Ltd.India
Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals
DRP-986-02
Jun 13, 2027
AnerobizolMetronidazole
5 mg/mL Solution for Intravenous InfusionPolypropylene Plastic Container x 100mL Box of 1's
Rx
Amanta Healthcare Ltd.India
Endure Medical, Inc.
DR-XY32881
Feb 21, 2031
AntizoalMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
Aglobal Care, Inc.
DRP-5460
Jul 31, 2028
ApzoleMetronidazole
500 mg/100 mL Solution for I.V. InfusionPolypropylene Plastic Bottle x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co. LtdChina
Pharmazel Inc.Importer: Apothecon Drug Int’l Corp.Trader: Shanghai Pharmaceutical Co., Ltd.
DRP-6583
Aug 14, 2028
AxagylMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
Sonchel Pharma DistributorsImporter: Ambica International Corporation
DRP-6449
Mar 5, 2030
Axamet-IVMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionLow Density Polyethylene (LDPE) Plastic Bottle x 100 mL (net content) (Box of 1's)
Rx
Axa Parenterals LimitedIndia
Brady Pharma Inc.
DRP-8507
Oct 22, 2029
BacdazoleMetronidazole
500 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's)
Rx
Scheele Laboratories Phils., Inc.Philippines
—
DRP-3941
Jan 24, 2032
BacimexMetronidazole
500 mg/100 mL (0.5% w/v) Solution for InjectionPlastic Bottle x 100 mL (Box of 1's)
Rx
Otsuka Pharmaceutical India Private LimitedIndia
Zuellig Pharma CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc.
DRP-1541
Apr 25, 2028
BerrydazoleMetronidazole (As Benzoate)
250 mg/5mL Oral SuspensionAmber boston round glass bottle with white aluminum screw cap x 30 mL (net content) & 60 mL (net content) [Box of 1's]
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Folares Pharmaceuticals, Inc.
DR-XY47509
Nov 29, 2026
BestdazoleMetronidazole
5 mg /mL (500 mg/100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Best ClearImporter: Euro-Care Products Philippines
DRP-8546-02
Nov 6, 2029
BluemedzoleMetronidazole
5 mg / mL (500 mg/100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Blue Medceuticals Marketing Corp.Importer: Euro-Care Products Philippines
DRP-8546-03
Nov 6, 2029
CetazMetronidazole
5 mg/mL (500mg/100mL) Solution for Injection (IV Infusion)LDPE vial X 100 mL Box of 1's
Rx
AISHWARYA HEALTHCAREIndia
QUALIFIRST HEALTH INC.Trader: ALKEM LABORATORIES LTD.
DRP-541
May 19, 2027
CoremedazoleMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Core Fidelis Pharmaceutical, Inc.Importer: AGlobal Care, Inc.
DRP-13577-05
Mar 13, 2028
DarylMetronidazole (as benzoate)
125 mg/5 mL Oral Suspension60 mL Amber Glass Bottle (Box of 1's)
Rx
Azarias Pharmaceutical Laboratories, Inc.Philippines
—
DRP-5275
Aug 15, 2030
DazoledMetronidazole
500 mg Film-Coated TabletAlu/Green PVC Blister Pack x 10’s (Box of 100’s)
Rx
Genom Biotech Pvt. Ltd.India
Eliset Pharmaceutical, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-17141-01
Oct 7, 2030
DazometMetronidazole
500 mg Film-Coated TabletAluminum Foil Strip x 4's Box of 100's
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY33848
Dec 2, 2028
DazometMetronidazole
500 mg/100 mL Solution For Iv InfusionUSP Type I clear glass vial with gray rubber closure and aluminum overseal cap with blue flip-off cap x 100 mL (Box of l’s)
Rx
Amherst Parenterals, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY33847
Aug 5, 2027
DelexigylMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL LDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
Delex Pharma International, Inc.Importer: Ambica International Corporation
DRP-6449-02
Mar 5, 2030
DymetrazoleMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Nurturemed Pharma Inc.Trader: Eadriex Pharmaceuticals Phils., Inc.
DRP-2420-02
Feb 17, 2027
DynazoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
DYNASTY PHARMACEUTICALSImporter: Aglobal Care, Inc.
DRP-5460-02
Jul 31, 2028
EastmezolMetronidazole
5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India
Core Fidelis Pharmaceutical, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4259-03
May 19, 2037
EndiglyMetronidazole
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6166
Jun 15, 2030
ErzolMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content). (Box of 1's.)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-8458
Oct 10, 2029
EurogylMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. Infusion100 mL USP Type III clear and colorless glass infusion bottle (Box of 1's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Euro-Care Products Philippines
DR-XY45126
Feb 23, 2031
EurometMetronidazole
500 mg/100 mL (5 mg/mL) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-4800
Mar 18, 2031
FlagexMetronidazole
500mg TabletBlister Pack x 10's (Box of 100's)
Rx
New Myrex Laboratories, Inc.Philippines
—
DRP-1001
Jan 30, 2028
FlagidinMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-4034-07
Sep 24, 2028
FlagimaxMetronidazole
500 mg TabletPaper Foil Strip x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Alberta's Pride International Indigo, Inc.
DR-XY47671
Jan 19, 2027
FlagylMetronidazole
1 mg/mL (500 mg/100 mL) Solution for I.V. infusionPoly (vinylchloride) flexible plastic bag (Viaflex) in 100 mL (net content) with transparent polypropylene overpouch
Rx
Baxter Healthcare S. A.Ireland
Importer: SANOFI-AVENTIS PHILIPPINES, INC
DRP-182
Nov 21, 2027
FlagylMetronidazole (as Benzoate)
125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
SANOFI-AVENTIS PHILIPPINES, INCTrader: Eadriex Pharmaceuticals Phils., Inc.
DRP-5591-05
Feb 7, 2028
FlagylMetronidazole (as benzoate)
25 mg/mL Oral Suspension60 mL Amber Glass Bottle with Gold Pilfer-proof Metal Cap (Box of 1's)
Rx
PT. Guardian PharmatamaIndonesia
Importer: Sanofi-Aventis Philippines, Inc.Trader: PT. Aventis Pharma
DR-9040
Mar 23, 2027
Flagyl ForteMetronidazole
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
PT Kalventis Sinergi FarmaIndonesia
Importer: sanofi-aventis Philippines, Inc.
DRP-009
Mar 12, 2031
FlagyzoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionUSP Type II Glass Vial x 100 mL (Box of 1's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DR-XY45437
Jun 10, 2031
Flamibazid 500Metronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-986
Jun 13, 2027
FlatroMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-6449-10
Mar 5, 2030
FlazoleMetronidazole (as Benzoate)
125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
8th Green Care Pharma Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-5591-02
Feb 7, 2028
ForamebexMetronidazole
125 mg/5mL SuspensionAmber Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Solvang Pharmaceuticals, Inc.Trader: Foramen Products Corporation
DR-XY21875
Oct 22, 2030
FrotinMetronidazole
250 mg Vaginal SuppositoryPVC Peel-off Container x 10's (Box of 100's)
Rx
Y.S.P. Industries (M) SDN. BHD.Malaysia
Importer: Yung Shin (Philippines), Inc.
DR-XY47819
Mar 15, 2027
G-TrozoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for IV InfusionFFS LDPE Bottle x 100 mL (Box of 1's)
Rx
Ahlcon Parenterals (India) Ltd.India
GPC Geo Pharma CorporationImporter: I.E. Medica, Inc.
DRP-5629-01
Oct 17, 2029
GodazoleMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation
DRP-6449-09
Mar 5, 2030
GonidazoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for IV InfusionPlastic Container x 100 mL (Box of 1's)
Rx
Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India
Applied Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc.
DRP-8098-01
Sep 27, 2028
GorondazMetronidazole
5 mg / mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content) (Box of 1's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Applied Pharmaceutical Distribution IncImporter: AMB HK Enterprises Inc.
DRP-8458-04
Oct 10, 2029
JinzoleMetronidazole (as Benzoate)
125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-5591
Feb 7, 2028
JinzoleMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Eadriex Pharmaceuticals Phils., Inc.
DRP-2420
Feb 17, 2027
MedgylMetronidazole
125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DR-XY18460
Apr 30, 2030
MedgylMetronidazole
5 mg/mL (500 mg/100 mL) Solution for Injection (I.V. Infusion)Type II Clear and Colorless Glass Vial x 100 mL (Box of 1's)
Rx
Taiwan Biotech Co., Ltd.China
Medhaus Pharma, IncorporatedImporter: Interhealthcare Pharmaceuticals, Inc.
DR-XY33042
Feb 26, 2027
MedgylMetronidazole
500 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma Inc.
DR-XY24567
Oct 27, 2028
Medgyl IVMetronidazole
500 mg /100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL Box of 1's
Rx
Ahlcon Parenterals (India) Ltd.India
Medhaus Pharma, IncorporatedImporter: I.E. Medica Inc.
DRP-5630-02
Oct 17, 2029
MedicazolMetronidazole
5 mg/mL (500 mg/100 mL) Solution For I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1's)
Rx
Shijiazhuang No.4 Pharmaceutical Co., Ltd.China
Medicamenta Inc.Importer: Aglobal Care, Inc.
DRP-5460-03
Jul 31, 2028
MedizoleMetronidazole
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's)
Rx
Medico Remedies LimitedIndia
Medethix, Inc.
DRP-6688
May 20, 2029
MedzolMetronidazole
5 mg/mL (500 mg/100 mL) Solution for Intravenous Infusion (I.V.)Polypropylene Infusion bottle with pull open cover x 100 mL (Box of 1’s)
Rx
SHIJIAZHUANG NO.4 PHARMACEUTICAL CO., LTD.China
APOTHECON DRUG INT’L CORP.Trader: SHANGHAI PHARMACEUTICAL CO., LTD.
DR-XY43080
Mar 17, 2027
MenizoleMetronidazole (as Benzoate)
125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-5591-01
Feb 7, 2028
MenizoleMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-2420-01
Feb 17, 2027
MetametMetronidazole
500 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker’s Laboratories Inc.Philippines
—
DRP-5468
Feb 15, 2030
MetdazidMetronidazole
5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India
Euparex Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4259-02
Apr 16, 2037
METRAZOLMetronidazole
500 mg/100 mL Solution for I.V. InfusionPolypropylene infusion bottle (w/ pull open cover) x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co. LtdChina
D & G PharmaImporter: Apothecon Drug Int’l Corp.Trader: Shanghai Pharmaceutical Co., Ltd
DRP-4192
Aug 14, 2028
Metrinox IVMetronidazole
500 mg per 100 mL Solution for Infusion (IV)Type II Glass Bottle with rubber stopper and blue flip-off seal x 100 mL (Box of 1's)
Rx
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY29518
Nov 14, 2036
MetrisMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionNon PVC (Polypropylene) Bag x 100 mL
Rx
OTSUKA PHARMACEUTICAL INDIA PRIVATE LIMITEDIndia
OTSUKA (PHILIPPINES) PHARMACEUTICAL, INC.
DR-XY42249
Jul 23, 2028
Metro-BrillMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content). (Box of 1’s)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Rcbrilliant Pharma CorpImporter: AMB HK Enterprises Inc.
DRP-8458-06
Oct 10, 2029
MetrocareMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100mL (Box of 1's)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
Euro-Care Products PhilippinesImporter: Aglobal Care, Inc.
DRP-5460-04
Jul 31, 2028
MetroclearMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
CV Clearvue Pharma, Inc.Importer: Ambica International Corporation
DRP-6449-05
Mar 5, 2030
MetrocorMetronidazole
5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4259
Mar 8, 2038
MetrodenMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content) (Box of 1's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Cyden Medicale Trading Inc.Importer: AMB HK Enterprises Inc.
DRP-8458-02
Oct 10, 2029
MetrogemMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) Box of 1's
Rx
Furen Pharmaceutical Group Co., Ltd.China
West Wing Pharma Sales Inc.Importer: Euro-Care Products Philippines
DRP-8546
Nov 6, 2029
MetrogilMetronidazole
5 mg/mL Solution for Injection (I.V.)LDPE bottle x 100 mL (Box of 1's)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-7883
Oct 11, 2028
MetrogylMetronidazole
10 mg/g (1% w/w) Topical GelAluminum Tube x 10 g and 30 g (Box of 1's)
Rx
Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Limited)India
JBCPL Philippines Inc.
DRP-8314
Feb 24, 2028
MetrolevMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
HLM Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-6449-08
Mar 5, 2030
MetroneedMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Checktrade Pharma, Inc.Importer: Ambica International Corporation
DRP-4034-02
Sep 24, 2028
Metronex SMetronidazole
5 mg/mL (500 mg/100 mL) Solution For Injection (IV Infusion)Type-II Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Flip-off Cap x 100 mL (Box of 1's)
Rx
Cotec Healthcare Pvt. Ltd.India
Despina Pharma Inc.
DRP-18429
Jul 8, 2031
MetronizolMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Onicare Pharma Trading & General MerchandiseImporter: AGlobal Care, Inc.
DRP-13577-03
Mar 13, 2028
MetronovaMetronidazole
500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Celogen Generics Private Ltd. (Unit II)India
Medinova Pharmaceutical Inc.
DRP-11953
May 24, 2027
Metronova IVMetronidazole
5 mg/mL (500 mg/100 mL) Solution for IV InfusionPlastic Container x 100 mL (Box of 1's)
Rx
Unique Pharmaceutical Labs. (A Division of J.B. Chemicals & Pharmaceutical Ltd.)India
Medinova Pharmaceutical Inc.
DRP-8098
Sep 27, 2028
Metronova IVMetronidazole
5mg/mL (500mg/100mL) Solution for Injection (IV Infusion)White LDPE Bottle Sealed with Cap x 100mL in LDPE Plastic Film Pouche (Box of 1's) .
Rx
Eurolife Healthcare Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-17295
Nov 11, 2030
MetronyMetronidazole
5 mg / mL (500 mg / 100 mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Asianmeds, Inc.Importer: Euro-Care Products Philippines
DRP-8546-01
Nov 6, 2029
MetrosaphMetronidazole
5 mg/mL (500 mg/100 mL) Solution For Injection (IV Infusion)White LDPE Container Sealed with Cap x 100 mL (Box of 1's)
Rx
Althea Phama Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-12535
May 18, 2032
Metrosaph-500Metronidazole
500 mg Film-Coated TabletAlu/Green PVC Blister Pack x 10's (Box of 100's)
Rx
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17141
Oct 7, 2030
MetrosaveMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
Savelink Pharma And Trading Co.Importer: Aglobal Care, Inc.
DRP-5460-06
Jul 31, 2028
MetrosolMetronidazole
500 mg/100 mL Solution for I.V. Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Marion Laboratories (Pvt) Ltd.Pakistan
Sahar International Trading, Inc.
DR-XY39985
Mar 8, 2028
MetrotonMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
McTon Pharma Inc.Importer: AGlobal Care, Inc
DRP-13577-06
Mar 13, 2028
MetroveeMetronidazole
5 mg/mL (500 mg/100 mL) Solution for Injection (IV Infusion)Transparent PP Infusion Bottle Sealed with Cap x 100 mL (Box of l's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Euro-Care Products Philippines
DRP-12534
Aug 30, 2027
MetroviaMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
Basic Pharmaceutical CorporationImporter: Aglobal Care, Inc.
DRP-5460-07
Jul 31, 2028
MetrovinMetronidazole
5 mg/mL Solution for I.V. InfusionLDPE Plastic Bottle x 100 mL (net content) (Box of 1's)
Rx
Aishwarya HealthcareIndia
Arvincare Pharma Inc
DRP-5560
Feb 3, 2027
MetroxcelMetronidazole
5 mg/mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Excelpharm CorporationImporter: Aglobal Care, Inc.
DRP-13577-04
Mar 13, 2028
MetroxidMetronidazole
5 mg/mL (500 mg/100 mL) Solution for IV Infusion100 mL USP Type II Clear and Colorless Glass Vial (Box of 1's)
Rx
Utopian Co., Ltd.Thailand
Lakeside Pharmaceuticals Phil., Inc.
DR-XY32450
Jul 3, 2030
MetrozedMetronidazole (as benzoate)
125mg/5mL Oral SuspensionDark Amber Color PET Bottle Sealed with ROPP Cap x 60mL, 100mL and 120mL (Box of 1's)
Rx
S Kant Healthcare Ltd.India
Medinova Pharmaceutical Inc.
DRP-17084
Sep 23, 2030
MetrozenMetronidazole
5 mg / mL (500 mg / 100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content). (Box of 1's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Genzen Pharmaceutical TradingImporter: AMB HK Enterprises Inc.
DRP-8458-05
Oct 10, 2029
MetrozoleMetronidazole (as benzoate)
125 mg/5 mL SuspensionAmber Boston Round Bottle x 60 mL Box of 1's
Rx
Diamond Laboratories Inc.Philippines
Rilem Pharma Corp.
DRP-7068
Oct 5, 2027
MetrozoleMetronidazole
500 mg TabletAlu/PVC Blister pack x 20's (Box of 100’s)
Rx
Diamond Laboratories Inc.Philippines
Rilem Pharma Corp.
DRP-7107
Jul 16, 2027
MetrynalMetronidazole
5 mg/mL (500 mg/ 100 mL) Solution for Injection (IV Infusion)USP Type II colorless and transparent glass bottle with bromobutyl rubber closure and aluminum cap x 100 mL (net content) Box of 10's
Rx
Dai Han Pharm. Co., Ltd.Republic of Korea
JLT PHARMA INC.
DRP-8759
Mar 11, 2031
MetzoleMetronidazole
500 mg TabletClear PVC Blister Pack x 10's (Box of 100's)
Rx
Drugmaker's Laboratories Inc.Philippines
—
DRP-8249
Jul 15, 2031
MistolMetronidazole
500 mg Vaginal SuppositoryWhite PVC/ PE Strip of 5's (Box of 10's)
Rx
Kusum Healthcare Pvt. Ltd (Block II)India
Kusum Healthcare Private Limited Branch Office
DR-XY46738
Mar 13, 2030
MoniliasolMetronidazole (as Benzoate)
125 mg/ 5 mL SuspensionAmber Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DR-XY24088
Apr 26, 2030
MoniliasolMetronidazole (as Benzoate)
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
LLOYD LABORATORIES, INC.Philippines
Trader: VITALINK HEALTH PRODUCTS, INC.
DR-XY19237-B
Oct 27, 2030
MordoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1's)
Rx
SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD.China
ELLEBASY MEDICALE TRADINGImporter: AGLOBAL CARE, INC
DRP-5460-01
Jul 31, 2028
Navgyl ForteMetronidazole
500 mg tabletAlu-PVC blister Pack x 10's (Box of 100's)
Rx
Scheele Laboratories Phils., Inc.Philippines
JN Carlo Pharmaceuticals Distributor
DRP-3941-01
Jan 24, 2027
Navgyl-500Metronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
JN Carlo Pharmaceuticals DistributorImporter: Aglobal Care, Inc.
DRP-13577-02
Mar 13, 2028
NeorobiaMetronidazole
5 mg/mL (500mg/100mL) Solution for I.V. InfusionClear glass bottle x 100 mL (net content) (Box of 1's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Neo Care Philippines, Inc.Importer: Euro-Care Products Philippines
DRP-8546-04
Nov 6, 2029
NeorobicMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL Box of 1’s
Rx
AXA Parenterals LimitedIndia
Neo-Care PhilippinesImporter: Ambica International Corporation
DRP-6449-07
Mar 5, 2030
NEOROBICMetronidazole
5mg/mL (500mg/100mL) Solution for Injection (IV Infusion)White LDPE Bottle Sealed with Cap x 100mL in LDPE Plastic Film Pouch Box of 1's
Rx
Eurolife Healthcare Pvt. Ltd.India
Neo Care Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-17295-01
Nov 11, 2030
NewmetMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
United Pharma Plus (Unipharma) Inc.Importer: Ambica International Corporation
DRP-4034-06
Sep 24, 2028
NewmetMetronidazole
500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL
Rx
Ahlcon Parenterals (India) Ltd.India
United Pharma Plus Inc.Importer: I.E. Medica, Inc.
DRP-5630
Oct 17, 2029
NicozoleMetronidazole
5 mg/mL Solution for I.V. InfusionLDPE Plastic Bottle x 100 mL (net content) (Box of 1's)
Rx
Aishwarya HealthcareIndia
Thymed EnterprisesImporter: Arvincare Pharma Inc
DRP-5560-01
Feb 3, 2027
NicozoleMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL Box of 1’s
Rx
AXA Parenterals LimitedIndia
Thymed EnterprisesImporter: Ambica International Corporation
DRP-6449-11
Mar 5, 2030
NidazMetronidazole
5 mg/mL (500 mg/100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Aglobal Care, Inc.
DRP-13577
Mar 13, 2028
NidazoprimeMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-6449-01
Mar 5, 2030
NirmetMetronidazole
Solution for Intravenous Infusion 5 mg/mL (500 mg/100 mL)LDPE bottle x 100 mL Box of 1's
Rx
Aculife Healthcare Private LimitedIndia
Brady Pharma Inc.
DR-XY38936
Jan 7, 2031
NoneMetronidazole (as Benzoate)
125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Scheele Laboratories Phils. Inc.Philippines
—
DRP-2059
Mar 12, 2031
NoneMetronidazole (as Benzoate)
125 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-5469-01
Mar 12, 2027
NoneMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for Intravenous Infusion100 mL LDPE Bottle (Box of 1's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Connectwell Pharma Inc.Importer: Aglobal Care, Inc.
DRP-13577-07
Mar 13, 2028
NoneMetronidazole
5 mg/mL (0.5% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India
RiteMED Phils., Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-4259-04
Apr 16, 2037
NoneMetronidazole
500 mg Solution for I.V. InfusionPlastic Container x 100 mL (Twin Port - Ecoflac Plus)
Rx
B. Braun Medical Industries Sdn. Bhd.Malaysia
B. Braun Medical Supplies, Incorporated
DR-XY14162
Feb 9, 2031
NoneMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s)
Rx
Stallion Laboratories Pvt. Ltd.India
PharmaVital Corp.Importer: Ambica International Corporation
DRP-12008-01
May 30, 2027
NoneMetronidazole
500 mg TabletAlu / PVC Blister Pack x 10's (Box of 100’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-12008-02
May 30, 2027
NoneMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
AM-Europharma CorporationPhilippines
—
DRP-2377
Apr 28, 2029
NoneMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-4034-05
Sep 24, 2028
NoneMetronidazole
500 mg TabletAlu/Clear PVC Blister pack x 10's and 20's (Box of 100's)
Rx
Drugmaker's Laboratories, Inc.Philippines
Drugmaker's Laboratories, Inc.
DRP-5468-02
Feb 15, 2030
NoneMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Flamingo Pharmaceuticals Ltd.India
Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals
DRP-986-03
Jun 13, 2027
NoneMetronidazole
500 mg/100 mL Solution for I.V. Infusion100 mL Type II Glass Vial with Blue Flip-off Cap
Rx
Grand Pharmaceutical (China) Co., Ltd.China
First Global Trading Corporation
DR-XY42300
Aug 1, 2028
NoneMetronidazole
500 mg/100 mL Solution for IV InfusionPolypropylene Bottle x 100 mL
Rx
Sichuan Kelun Pharmaceutical Co., Ltd.China
Sahar International Trading, Inc,Importer: Nueva Sunshine Phils., Inc.
DRP-7705
Sep 1, 2030
OnizoleMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Starpharm, Inc.Importer: Ambica International Corporation
DRP-4034-03
Sep 24, 2028
Onizole VialMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
Starpharm, Inc.Importer: Ambica International Corporation
DRP-6449-04
Mar 5, 2030
PatrizoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for Intravenous InfusionUSP Type II Glass Vial x 100 mL (Box of 1's)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Nutramedica Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-16242-02
Jun 10, 2031
PatrylMetronidazole (as Benzoate)
125 mg/5 mL Suspension (Strawberry Flavor)Amber Bottle x 15 mL and 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Nutramedica, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-2440
Apr 30, 2030
PatrylMetronidazole
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Nutramedica Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-3377
Mar 9, 2030
PolgylMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle with LHDPE twin bag port and cap x 100mL (net content). Box of 1’s.
Rx
Polifarma Ilac San. Ve Tic A.S.Turkey
Endure Medical, Inc.
DR-XY48034
May 20, 2027
Progyl DsMetronidazole
500 mg Film-Coated TabletAlu/Deep Red PVC PVC Film Blister Pack of 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
ATC Healthcare International Corp.
DRP-14448
Sep 6, 2028
ProtozoleMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's)
Rx
Stallion Laboratories Pvt. LtdIndia
The Cathay Drug Co., IncImporter: Ambica International Corporation
DRP-4034
Sep 24, 2028
ProtozoleMetronidazole
500 mg/100 mL (0.5% w/v) Solution for InjectionPlastic Bottle x 100 mL (Box of 1's)
Rx
Otsuka Pharmaceutical India Private LimitedIndia
The Cathay Drug Co., Inc.Importer: Otsuka (Philippines) Pharmaceutical, Inc.
DRP-1541-02
Apr 25, 2028
ProtozoleMetronidazole
500 mg/100 mL Solution for Intravenous InfusionFFS LDPE Bottle x 100 mL Box of 1's
Rx
Ahlcon Parenterals (India) Ltd.India
The Cathay Drug Co., Inc.Importer: I.E. Medica, Inc.
DRP-5629-02
Oct 17, 2029
Q-ZolMetronidazole (as Benzoate)
125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Quad-Gen PharmaceuticalsTrader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-5591-03
Feb 7, 2028
QuinozoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for IV InfusionFFS LDPE Bottle x 100 mL (Box of 1's)
Rx
Ahlcon Parenterals (India) Ltd.India
MeedPharma Medical Supplies & Equipment DistributorImporter: I.E. Medica, Inc.
DRP-5629
Oct 17, 2029
RetazolMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1's)
Rx
Shijiazhuang No.4 Pharmaceutical Co., Ltd.China
Reta DrugImporter: Aglobal Care, Inc.
DRP-5460-05
Jul 31, 2028
RicozoleMetronidazole (as Benzoate)
125 mg/5 mL Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Pharmahealth EnterprisesTrader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-5591-04
Feb 7, 2028
RicozoleMetronidazole
500 mg TabletBlister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Pharmahealth EnterprisesTrader: Eadriex Pharmaceuticals Phils., Inc.
DRP-2420-03
Feb 17, 2027
RockzoleMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for I.V. InfusionPolypropylene Bottle x 100 mL (Box of 1’s)
Rx
Shijiazhuang No. 4 Pharmaceutical Co., LtdChina
Redrocks Pharma and Medical Supplies DistributionImporter: AGlobal Care, Inc.
DRP-5460-08
Jul 31, 2028
RodazidMetronidazole
125 mg / 5 mL SuspensionAmber Glass Bottle x 60 mL and 120 mL Box of 1's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: PNSV ASIA CORPORATION
DR-XY22116
Apr 30, 2031
RodazidMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s
Rx
Lloyd Laboratories, Inc.Philippines
Trader: PNSV ASIA CORPORATION
DR-XY18633
Apr 13, 2029
Siti-zoleMetronidazole
5 mg/mL (500 mg/ 100 mL) Solution for I.V. Infusion.Polypropylene plastic infusion bottle x 100 (net content) Box of 's
Rx
Shijiazhuang No. 4 Pharmaceutical Co., LtdChina
Sahar International Trading Inc.
DR-XY47985
Apr 28, 2027
Siti-zoleMetronidazole
5 mg/mL (500 mg/100 mL) Solution for I.V. InfusionPolypropylene plastic infusion bottle x 100 (net content) (Box of 1's)
Rx
Shijiazhuang No.4 Co., Ltd.China
Sahar International Trading Inc.
DRP-16719
Apr 28, 2027
Strozole-500Metronidazole
500 mg TabletAlu/PVC Blister Pack x 10's Box of 30's and 100's
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4034-01
Sep 24, 2028
SydenzoleMetronidazole
500 mg TabletPaper Foil Strip x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Sydenham Pharmaceuticals, Inc.
DRP-11633
Jan 19, 2027
TG-ZOLEMetronidazole
500 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's)
Rx
Scheele Laboratories Phils., Inc.Philippines
TGIF Pharmaceutical Trading Inc.
DRP-3941-02
Jan 24, 2027
Triconex ForteMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation
DRP-4034-04
Sep 24, 2028
Trimetro IVMetronidazole
5mg/mL Solution for Injection (IV Infusion)Transparent Colorless LDPE Bottle x 100 mL (Box of 1's)
Rx
Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India
S.M.H.P. Marketing & Consultancy
DRP-13543
Mar 8, 2028
TrinosaphMetronidazole (as benzoate)
10 mg/g (1 % w/w) Topical GelLaminated Plastic Tube X 10g, 20g and (Box of 1's)
Rx
Azine Healthcare Pvt. Ltd.India
Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13395
Feb 10, 2028
TrozodazMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
Central West Medicale Inc.Importer: Ambica International Corporation
DRP-6449-06
Mar 5, 2030
UnbrandedMetronidazole
500 mg Film-Coated TabletAlu/Green PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-11208
Feb 15, 2032
UnbrandedMetronidazole
500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
New Myrex Laboratories, Inc.Philippines
—
DRP-10685
Nov 5, 2031
UnbrandedMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Am-Europharma CorporationPhilippines
Ritemed Phils., Inc.
DRP-2377-01
Apr 28, 2029
VitazolMetronidazole
5 mg/ mL (500 mg/ 100 mL) Solution for I.V. InfusionPolypropylene (PP) plastic bottle x 100 mL (net content) (Box of 1's)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Vitalis Pharma Phil. Corp.Importer: AMB HK Enterprises Inc.
DRP-8458-01
Oct 10, 2029
XylomidMetronidazole
500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-12008
May 30, 2032
ZolMetronidazole
500 mg/100 mL Solution for Intravenous Infusion
Rx
Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY49641
Feb 20, 2031
ZolegylMetronidazole
500 mg/100 mL (0.5% w/v) Solution for IV InfusionLDPE plastic container x 100 mL (Box of 1’s)
Rx
AXA Parenterals LimitedIndia
D&G PharmaImporter: Ambica International Corporation
DRP-6449-03
Mar 5, 2030
ZolemetMetronidazole
5 mg/mL Solution for IV InfusionType II Soda Lime Glass Bottle x 100 mL Not Applicable
Rx
Shandong Qidu Pharmaceutical Co., Ltd.China
Endure Medical, Inc.Trader: Xiamen Runcheng Group Co., Ltd.
DR-XY44760
Sep 11, 2030
ZolpasMetronidazole
500 mg/100 mL Solution for I.V. InfusionLDPE Clear FFS Bottle x 100 mL (Box of 1’s)
Rx
Eurolife Healthcare Pvt. Ltd.India
Hexagon Pharmaceuticals
DR-XY47205
Mar 19, 2031
(no brand name)Metronidazole (As Benzoate)
125 mg / 5 mL Oral SuspensionAmber boston round glass bottle with white aluminum screw cap x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-11289
Feb 23, 2027
(no brand name)Metronidazole
500 mg Film-Coated TabletAlu/Deep Red PVC PVC Film Blister Pack of 10's (Box of 10's, 30's and 100's)
Rx
Phil. United Pharma CorporationPhilippines
—
DRP-14447
Sep 6, 2028
(no brand name)Metronidazole
500 mg Film-Coated TabletAlu/PVC Deep Red Film Blister Pack of 10’s (Box of 10's, 30's and 100's)
Rx
PHIL. UNITED PHARMA CORPORATIONPhilippines
Trader: Docteur's Choice Corporation
DRP-14449
Sep 6, 2028
(no brand name)Metronidazole
500 mg Film-Coated TabletAlu/Deep Red PVC Film Blister Pack of 10's (Box of 10's, 30's and 100's)
Rx
PHIL. UNITED PHARMA CORPORATIONPhilippines
Trader: Golden Dale Pharma Corp.
DRP-14450
Sep 6, 2028
(no brand name)Metronidazole
500 mg per 100 mL Solution For Iv InfusionPOLYPROPYLENE INFUSION BOTTLE
Rx
—
—
DRP-13486
Feb 27, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of metronidazole. Symptoms can be serious and potentially life threatening.

If symptoms or signs of SCARs develop, discontinue Metronidazole injection immediately and institute appropriate therapy. Central and Peripheral Nervous System Effects Severe neurological disturbances, including encephalopathy, cerebellar symptoms, convulsive seizures, peripheral neuropathy, optic neuropathy, and aseptic meningitis, have been reported in patients treated with metronidazole.

Encephalopathy associated with metronidazole may manifest as confusion or decreased level of consciousness, and is associated with widespread lesions on magnetic resonance imaging (MRI) of the brain. Cerebellar toxicity associated with metronidazole may manifest as ataxia, dizziness, dysarthria, nystagmus and saccadic pursuit and is accompanied by T2 flair lesions within the dentate nuclei seen on MRI.

Cerebellar toxicity may concurrently occur with encephalopathy, peripheral neuropathy or seizures. CNS symptoms and CNS lesions are generally reversible within days to weeks upon discontinuation of Metronidazole Injection. Peripheral neuropathy, usually symmetric and mainly of sensory type is characterized by numbness or paresthesia of an extremity.

Symptoms may be prolonged after drug discontinuation. Aseptic meningitis may occur within hours of dose administration and generally resolve after metronidazole therapy is discontinued (see ADVERSE REACTIONS). Advise patients to report neurologic symptoms that occur during metronidazole administration. Discontinue metronidazole treatment if any abnormal neurologic symptoms occur such as ataxia, dizziness, confusion or any other CNS adverse reaction (see ADVERSE REACTIONS).

Drug interactions

Drug or classSeverityEffectWhat to do
DisulfiramAvoidPsychotic reactions and confusion (label).Contraindicated within 2 weeks of disulfiram.
Alcohol or propylene glycol productsAvoidDisulfiram-like reaction (label).Avoid during and for 3 days after therapy.
WarfarinAdjust or monitorHigher INR and bleeding risk (label).Monitor INR; adjust warfarin.
LithiumAdjust or monitorHigher lithium levels and possible kidney damage (label).Monitor lithium and creatinine.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

Drug Interactions

  • Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS).
  • Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS).
  • Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this type of anticoagulant therapy, prothrombin time and international normalized ratio (INR) should be carefully monitored and their anticoagulant dose adjusted accordingly. Monitor patients for signs and symptoms of bleeding.
  • Lithium In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Lithium toxicity may lead to renal damage. Frequent monitoring of serum lithium and serum creatinine levels is necessary.
  • Busulfan Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity such as sinusoidal obstruction syndrome, gastrointestinal mucositis, and hepatic veno-occlusive disease. Metronidazole Injection should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly.
  • Drugs that Inhibit CYP450 Enzymes The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may decrease metabolism and reduce plasma clearance of metronidazole which may result in metronidazole toxicity.
  • Drugs that Induce CYP450 Enzymes The simultaneous administration of drugs that induce microsomal liver enzyme activity, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole and therefore decrease its efficacy.
  • Cytochrome P450 3A4 (CYP3A4) substrates Concomitant use of Metronidazole Injection and CYP3A4 substrates (e.g., amiodarone, tacrolimus, cyclosporine, carbamazepine, phenytoin, and quinidine) may increase respective CYP3A4-substrate plasma levels. Monitoring of plasma concentrations of CYP3A4 substrates may be necessary.
  • 5-Fluorouracil Metronidazole Injection decreases the clearance of 5-fluorouracil and may therefore cause 5-fluorouracil toxicity.
  • Vecuronium Metronidazole Injection may potentiate the effects of vecuronium.
  • Drugs that Prolong the QT interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval.
  • Drug/Laboratory Test Interactions Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides and glucose hexokinase. Metronidazole causes an increase in ultraviolet absorbance at 340 nm resulting in falsely decreased values.

Adverse reactions

Common

  • Vaginal candidiasis
  • Decreased appetite
  • Confusion, insomnia (listed reactions; no rates given)

Serious

  • Severe cutaneous adverse reactions (TEN, SJS, DRESS, AGEP)
  • Encephalopathy, cerebellar toxicity, seizures, peripheral and optic neuropathy, aseptic meningitis
  • Severe hepatotoxicity in Cockayne syndrome
  • Leukopenia, neutropenia
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The following reactions have been reported during treatment with metronidazole formulations: INFECTIONS AND INFESTATIONS: Vaginal candidiasis BLOOD AND LYMPHATIC SYSTEM DISORDERS: Agranulocytosis, Leukopenia, Neutropenia, Thrombocytopenia, Eosinophilia IMMUNE SYSTEM DISORDERS: Anaphylactic reaction, Hypersensitivity METABOLISM AND NUTRITION DISORDERS: Decreased appetite PSYCHIATRIC DISORDERS: Confusional state, Depression, Insomnia, Decreased libido NERVOUS SYSTEM DISORDERS: Encephalopathy, Seizure, Neuropathy peripheral, Ataxia, Dizziness, Hypoesthesia, Paresthesia, Dysgeusia, Headache, Nystagmus, Aseptic meningitis, Somnolence, Dysarthria, Numbness, Syncope EYE DISORDERS: Optic neuropathy, Saccadic eye movement EAR AND LABYRINTH DISORDERS: Vertigo, tinnitus, hearing impairment, hearing loss CARDIAC DISORDERS: QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. Flattening of the T-wave may be seen in electrocardiographic tracings, Tachycardia, Palpitation RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS: Dyspnea GASTROINTESTINAL DISORDERS: Pancreatitis, Abdominal pain, Diarrhea, Nausea, Vomiting, Asthenia, Proctitis HEPATOBILIARY DISORDERS: Hepatotoxicity/Liver Failure in patients with Cockayne syndrome (see CONTRAINDICATIONS), Jaundice SKIN AND SUBCUTANEOUS DISORDERS: Toxic epidermal necrolysis, Swelling face, Pruritus, Urticaria, Hyperhidrosis, Erythema, Rash; Stevens-Johnson syndrome, Fixed drug eruption, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) (see WARNINGS) MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: Muscle spasms, Arthralgia, Myalgia RENAL AND URINARY DISORDERS: Chromaturia, Dysuria Hepatic: Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne Syndrome (latency from drug start to signs of liver failure as short as 2 days) (see CONTRAINDICATIONS) REPRODUCTIVE: Dyspareunia GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Injection site reaction, Malaise, Face edema, Edema peripheral, Chest pain, Chills INVESTIGATIONS: Hepatic enzyme increased.

Patients with Crohn's disease are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn's disease patients who have been treated with metronidazole at high doses for extended periods of time.

A cause and effect relationship has not been established. Crohn's disease is not an approved indication for Metronidazole Injection.

Monitoring parameters

  • Neurologic symptoms (encephalopathy, cerebellar signs, seizures, peripheral or optic neuropathy, aseptic meningitis); liver function in hepatic impairment; INR with warfarin; lithium and creatinine with lithium (label). Kidney
  • Neurologic symptoms
  • Blood counts in long courses
  • INR with warfarin
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects There are no adequate and well-controlled studies of Metronidazole Injection in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used metronidazole during pregnancy. Many studies included first trimester exposures.

One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in utero; however, these findings were not confirmed. In addition, more than ten randomized, placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for bacterial vaginosis on the incidence of preterm delivery.

Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited.

Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits and mice at doses similar to the maximum recommended daily dose based on body surface area comparisons. There was no evidence of harm to the fetus due to metronidazole.

Healthcare provider should carefully consider the potential risks and benefits for each specific patient before prescribing Metronidazole Injection.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. Because of the potential for tumorigenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Alternatively, a nursing mother may choose to pump and discard human milk for the duration of metronidazole therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula.

Mechanism of action

Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intra-cellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical.

Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of bacteria.

The precise mechanism of action of metronidazole is unclear.

US FDA label

Pharmacokinetics

Key PK parameters

Half-lifeAbout 8 hours
Half-life in kidney failure (ESKD) kidneyMetronidazole unchanged; hydroxy and acetate metabolites accumulate (label)
Protein bindingUnder 20%
Metabolism (CYP, transporters)Side-chain oxidation and glucuronide conjugation
Active metabolitesHydroxy metabolite (in vitro antimicrobial activity)
Renal excretion kidney60% to 80% of the dose in urine, about 20% of that as unchanged drug
Dialyzability kidneyHemodialysis yes; peritoneal dialysis minimal (label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

The average elimination half-life of metronidazole in healthy subjects is eight hours.

Excretion The major route of elimination of metronidazole and its metabolites is via the urine (60-80% of the dose), with approximately 20% of the amount excreted appearing as unchanged metronidazole.

Renal clearance of metronidazole is approximately 10 mL/min/1.73 m 2 .

Fecal excretion accounts for 6-15% of the dose.

The elimination half-life, measured during the first three days of life, was inversely related to gestational age.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY In patients treated with intravenous metronidazole, using a dosage regimen of 15 mg/kg loading dose followed 6 hours later by 7.5 mg/kg every 6 hours, the average peak steady-state plasma concentrations (C max) and trough concentrations (C min) were 25 mcg/mL and 18 mcg/mL, respectively. Plasma concentrations of metronidazole are proportional to the administered dose.

An eight-hour intravenous infusion of 100 mg to 4,000 mg of metronidazole in normal subjects showed a linear relationship between dose and peak plasma concentration. The average elimination half-life of metronidazole in healthy subjects is eight hours. Distribution Metronidazole is the major component appearing in the plasma, with lesser quantities of metabolites also being present.

Less than 20% of the circulating metronidazole is bound to plasma proteins. Metronidazole appears in cerebrospinal fluid, saliva and breast milk in concentrations similar to those found in plasma. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic abscesses. Following a single intravenous dose of metronidazole 500 mg, 4 healthy subjects who underwent gastrointestinal endoscopy had peak gastric juice metronidazole concentrations of 5 to 6 mcg/mL at one hour post-dose.

In patients receiving intravenous metronidazole in whom gastric secretions are continuously removed by nasogastric aspiration, sufficient metronidazole may be removed in the aspirate to cause a reduction in serum levels. Metabolism The metabolites of metronidazole result primarily from side-chain oxidation [1-(ß-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation.

Both the parent compound and the hydroxyl metabolite possess in vitro antimicrobial activity. Excretion The major route of elimination of metronidazole and its metabolites is via the urine (60-80% of the dose), with approximately 20% of the amount excreted appearing as unchanged metronidazole. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m².

Fecal excretion accounts for 6-15% of the dose. Renal Impairment Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. Subjects with end-stage renal disease (ESRD; CL CR = 8.1±9.1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of metronidazole acetate, compared to healthy subjects with normal renal function (CL CR = 126 ± 16 mL/min).

Thus, on account of the potential accumulation of metronidazole metabolites in ESRD patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS). Effect of Dialysis Following a single intravenous infusion or oral dose of metronidazole 500 mg, the clearance of metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

A hemodialysis session lasting for 4 to 8 hours removed 40% to 65% of the administered metronidazole dose, depending on the type of the dialyzer membrane used and the duration of the dialysis session. If the administration of metronidazole cannot be separated from the dialysis session, supplementation of metronidazole dose following hemodialysis should be considered (see DOSAGE AND ADMINISTRATION).

A peritoneal dialysis session lasting for 7.5 hours removed approximately 10% of the administered metronidazole dose. No adjustment in metronidazole dose is needed in ESRD patients undergoing CAPD. Hepatic Impairment Following a single intravenous infusion of 500 mg metronidazole, the mean AUC 24 of metronidazole was higher by 114% in patients with severe (Child-Pugh C) hepatic impairment, and by 54% and 53% in patients with a mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, respectively, compared to healthy control subjects.

There were no significant changes in the AUC 24 of hydroxy-metronidazole in these hepatically impaired patients. A reduction in metronidazole dosage by 50% is recommended in patients with severe (Child-Pugh C) hepatic impairment (see DOSAGE AND ADMINISTRATION). No dosage adjustment is needed for patients with mild to moderate hepatic impairment.

Patients with mild to moderate hepatic impairment should be monitored for metronidazole associated adverse events (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Geriatric Patients Following a single 500 mg oral or IV dose of metronidazole, subjects >70 years old with no apparent renal or hepatic dysfunction had a 40% to 80% higher mean AUC of hydroxy-metronidazole (active metabolite), with no apparent increase in the mean AUC of metronidazole (parent compound), compared to young healthy controls < 40 years old.

In geriatric patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS). Pediatric Patients In one study newborn infants appeared to demonstrate diminished capacity to eliminate metronidazole. The elimination half-life, measured during the first three days of life, was inversely related to gestational age.

In infants whose gestational ages were between 28 and 40 weeks, the corresponding elimination half-lives ranged from 109 to 22.5 hours. Two other trials included infants 23-48 weeks post-menstrual age, (0-80 days postnatal age) with complicated intra-abdominal infections. Clearance increased with increasing post-menstrual age, while volume of distribution and half-life decreased (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION).

Microbiology Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intra-cellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical.

Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of bacteria.

The precise mechanism of action of metronidazole is unclear. Drug Resistance A potential for development of resistance exists against metronidazole. Resistance may be due to multiple mechanisms that include decreased uptake of the drug, altered reduction efficiency, overexpression of the efflux pumps, inactivation of the drug, and/or increased DNA damage repair.

Metronidazole does not possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Activity In Vitro and in Clinical Infections Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

Gram-positive anaerobes Clostridium species Eubacterium species Peptococcus species Peptostreptococcus species Gram-negative anaerobes Bacteroides fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus) Fusobacterium species The following in vitro data are available, but their clinical significance is unknown. Metronidazole exhibits in vitro minimal inhibitory concentrations (MIC’s) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.

Gram-negative anaerobes Bacteroides fragilis group (B. caccae, B. uniformis) Prevotella species (P. bivia, P. buccae, P. disiens) Susceptibility Tests For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: http://www.fda.gov/STIC.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Metronidazole 5 mg/mL, 100 mL Vial₱12.11–₱57.00Reference ₱14.17per vialDPRI procurement range
Metronidazole 125 mg/5 mL, 60 mL Suspension₱15.00–₱69.00Reference ₱20.25per unitDPRI procurement range
Metronidazole 500 mg Tablet₱0.85–₱3.85Reference ₱1.20per tabletDPRI procurement range
125 mg/5 mL (as base) or 200 mg/mL (as benzoate) suspension in 60 mL₱81.50per unitPhilHealth GAMOT fixed fee
250 mg tablet₱11.00per tabletPhilHealth GAMOT fixed fee
500 mg tablet₱13.25per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Metronidazole
PNF listingOral: 250 mg and 500 mg tablet
PNF listingOral: 125 mg base/5 mL (200 mg/5 mL (as benzoate)) suspension, 60 mL
PNF listingInj.: 5 mg/mL, 100 mL vial (IV infusion)
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Metronidazole · Civica, Inc. [US FDA-approved label, version 2, November 21, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=902ab25b-d493-495a-884e-96b080e9f72d
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  7. Civica, Inc. (2025). Metronidazole injection USP [Prescribing information; US FDA-approved label, NDA018657, set ID 902ab25b-d493-495a-884e-96b080e9f72d, version effective November 21, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=902ab25b-d493-495a-884e-96b080e9f72d

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .